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Abstract
Factors (protein/lipid ratio, pH of incubation medium, incubation time, anchor molecule density in the bilayer) affecting the covalent 
binding of anti-ovarian carcinoma Fab' to liposomes containing the anchor molecule MPB-PE (N-(4-(p-maleimidophenyl)butyryl)phos- 
phatidylethanolamine) were explored. Standard experimental conditions were chosen and information on the relevant physicochemical 
parameters of the liposome dispersions was collected (mean particle diameter, size distribution, charge). The reproducibility of standard 
immunoliposomes prepared in subsequent batches in terms of Fab' binding, particle size and charge was established. In addition, 
preservation of immunoreactivity, no marker loss, and no aggregation/fusion was found for the standard immunoliposomes over a period 
of at least 3 weeks at 4°C. In vitro up to 35000 immunoliposomes were estimated to bind per human ovarian carcinoma cell. 
Internalization of the immunoliposomes could not be demonstrated. Electron micrographs showed binding of specific immunoliposomes 
to human ovarian carcinoma cells growing intraperitoneally in athymic nude mice.
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1. Introduction
In principle, the conjugation of cell-specific antibodies 
to liposomes containing chemotherapeutic agents provides 
the possibility for selective drug delivery and cell type 
specific cytotoxicity [1-4]. Indeed, such liposomes, re­
ferred to as immunoliposomes, have been shown to in­
crease cytotoxicity selectively in vitro in several murine 
tumor cell lines [5-10]. Only a limited number of studies 
investigated the possibility to direct immunoliposomes to 
specific cells or tissues in vivo [11-18]. From these studies 
the anatomical and physiological constraints interfering 
with successful site-specific delivery of drugs can be de­
rived. Maximum benefit of active targeting with immunoli­
posomes in vivo can be expected when the immunolipo-
Corresponding author. Fax: +31 30 517839.
1 UIPS is part of the research school Groningen Utrecht Institute for 
Drug Exploration (GUIDE).
somes are injected into the compartment where the target 
tissue or cells are localized.
Intraperitoneal (i.p.) administration of immunolipo­
somes containing tumoricidal agents has a strong phar­
macological and biological rationale for the treatment of 
ovarian cancer. Ovarian tumors usually spread over the 
serosal surfaces of the peritoneal cavity; dissemination via 
the blood circulation occurs later and less frequently. A  
major cause of death in ovarian cancer patients is the 
inability to control the disease within the peritoneal cavity. 
While the primary tumor and larger tumor nodules may be 
removed surgically, micronodular disease and floating tu­
mor colonies which are confined to the peritoneal cavity, 
cannot be treated adequately by surgery [19,20].
Immunoliposomes specifically directed against human 
ovarian carcinoma cells were prepared, characterized and 
tested for their binding capacity to human ovarian carci­
noma cells grown in vitro and in vivo. The effect of 
experimental variables on the liposome-cell interaction 
was quantified. These immunoliposomes were developed
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to interact in vivo after i.p. administration with ovarian 
carcinoma cells localized in the peritoneal cavity and to 
deliver antitumor drugs in or in close proximity of these 
target cells [39]. In this study electron microscopic evi­
dence was established for a specific interaction between 
immunoliposomes and the i.p. located target cells in 
athymic nude mice.
2. Materials and methods
2.1. Materials
Egg-L-a-phosphatidylcholine type V-E (PC), choles­
terol (Choi), 4-(2-hydroxyethyl)-l-piperazineethane- 
sulfonic acid (Hepes), dithiothreitol (DTT) and iV-ethyl- 
maleimide (NEM) were obtained from Sigma (St. Louis, 
MO, USA). Egg-phosphatidylglycerol (PG) was supplied 
by Nattermann (Cologne, Germany). Carboxyfluorescein 
(CF) was purchased from Eastman Kodak (Rochester, NY, 
USA) and was purified by the method described by Ral­
ston et al. [21]. [ la ,2 a (n )-3H]Cholesteryloleoylether 
(spec. act. 1.71 TBq/mmol) was supplied by Amersham 
(Buckinghamshire, UK). Soluene-350 and Hionic Fluor 
was purchased from Packard Instrument (Downers Grove, 
IL, USA). All other reagents were of analytical grade.
2.2. Monoclonal antibodies
Hybridomas producing the monoclonal antibodies OV- 
TL3 and RIV1000 (both of mouse IgGl type) were grown 
in BALB/c athymic nude mice [33,34]. The antibodies 
were purified and Fab' fragments were isolated as follows: 
mouse ascites was mixed with an equal volume of 
glycine/NaCl buffer (1.5 M glycine, 3.0 M NaCl, pH 8.9) 
and filtered through 0.2 /xm Minisart NML filters 
(Sartorius, Gottingen, Germany) before application onto a 
Protein A-Sepharose CL-6B column (Pharmacia AB, Upp­
sala, Sweden). The unbound material was removed from 
the column by washing with glycine/NaCl buffer until no 
further change in absorption at 280 nm was seen. The
monoclonal antibodies were eluted in mM citrate
buffer pH 5.0. The purified antibodies were pooled, neu­
tralized with 2 M Tris base solution, concentrated with a 
Centriprep 30 concentrator (Amicon, Danvers, MA, USA) 
and dialyzed overnight against acetate buffer (100 mM 
NaAc, pH 7.4) at 4°C. F(ab')2 fragments were produced 
by pepsin digestion. The pH of the purified IgG solution 
was adjusted to 4.2 immediately before digestion. Pepsin 
was added at a ratio of 1 mg per 30 mg of IgG. The 
mixture was incubated in a water bath at 37° C overnight. 
After adjusting the pH to 7.4 with 2 M Tris base solution 
the protein solution was mixed with glycine/NaCl buffer, 
filtered through a 0.2 /xm filter and applied onto a Protein 
A-Sepharose CL-6B column. The unbound fractions, 
mainly representing F(ab')2 fragments and pepsin, were
collected and concentrated. Finally, the concentrated pro­
tein solution was applied to a Superdex 200 pg (26 /60)  
column (Pharmacia) eluted with acetate buffer (100 mM 
NaAc, 88 mM NaCl, pH 7.4) in order to separate the 
F(ab')2 fragments from pepsin and residual amounts of Fc 
fragments and IgG. The F(ab')2 fragments were stored at 
— 20° C prior to use.
Purity of IgG and F(ab')2 was assessed by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS- 
PAGE) under non-reducing conditions with a PhastSystem
and Homogeneous 12.5 gels To
determine the apparent molecular weights low weight stan­
dards (Bio-Rad Laboratories, Richmond, CA, USA) were
used.
Isoelectric focusing (IEF) was performed with the same 
system using PhastGel IEF 3-9 gels (Pharmacia). The 
samples were routinely applied at the anodic side of the 
gel. The pH gradient over the gels was monitored with an 
IEF calibration kit (Pharmacia). Electrophoresis and silver 
staining were carried out according to manufacturer in­
structions.
The immunoreactivity was tested by flow cytometry. 
Cultured monolayers of OVCAR-4 cells (see below) were 
treated with trypsin/EDTA (0.25%/0.02%) and washed 
with Dulbecco’s phosphate-buffered saline (DPBS, Gibco, 
Paisley, UK). OV-TL3 or RIV1000 (IgG or F(ab')2) anti­
bodies were diluted in DPBS containing 0.1% NaN3 as 
indicated. Cells (5 • 105) were incubated at 4° C for 45 min 
in 50 /xl antibody solution. After incubation, cells were 
washed twice with DPBS by centrifugation (5 min, 800 X 
g) and incubated at 4° C for 45 min with 50 /xl fluores­
cein-conjugated goat anti-(mouse IgG) (Capel Labs, Cooper 
Biomedical, Malvern, PA, USA) at a dilution of 1:80. The 
cells were washed twice and fixed with 200 /xl 0.1% 
paraformaldehyde and kept on ice until fluorescence was 
measured. The percentage of fluorescent cells is presented 
after subtraction of the percentage of fluorescent cells 
stained after incubation with only fluorescein-conjugate. 
Fluorescence analysis was performed in a fluorescence- 
activated cell sorter (Becton & Dickinson Immunocytome-
try Mountain View, CA, USA). Analysis of the
data was performed with Consort 30 software (Becton & 
Dickinson) on a Hewlett Packard 9920 S Computer. Data 
were calculated for 104 cells after gating the dot plots of 
the volume-sidescatter diagram.
2.3. Preparation of Fab1 fragments
in 1
F(ab')2 fragments of OV-TL3 and RIV1000 (3 -4  mg) 
-1.5 ml of acetate buffer (100 mM NaAc, 88 mM 
NaCl, pH 5.5), were routinely reduced with 20 mM DTT 
at pH 5.5 for 90 min at room temperature under nitrogen 
atmosphere [22]. DTT was removed by gel chromatog­
raphy on a Sephadex G-25M column (PD-10, Pharmacia). 
Pre-equilibration and elution occurred with deoxygenated 
acetate buffer (100 mM NaAc. 88 mM NaCl, dH 6.5)
128 U.K. N'àssander et al. / Biochimica et Biophysica Acta 1235 (1995) 126-139
under nitrogen atmosphere. Fab' fragments appearing in
the void volume were used immediately for covalent at­
tachment to freshly prepared MPB-PE liposomes. Comple­
tion of the reduction process was checked by HPLC 
(TSK-3000 SW column, length 60 cm, LKB, Bromma, 
Sweden), after adding an excess of NEM to an aliquot of 
the resulting protein solution. The HPLC equipment con­
sisted of the following components: a solvent delivery 
system (Waters, model 6000A), a manual injector (Rheo- 
dyne, model 7125), a U V /V IS variable wavelength detec­
tor (Waters, model 450) operating at 280 nm. After injec­
tion of 25 /xl of the standards or the sample, the column 
was eluted isocratically with phosphate buffer (0.1 M, 0.1 
M KC1, pH 7.0) using a flow of 1 ml/min. The following 
standards were used for calibration: bovine serum albumin 
and its dimer ovalbumin, carbonic anhydrase, lactalbumin 
and insulin.
2.4. Preparation of (immuno)liposomes
jV-(4-( /?-Maleimidophenyl)butyryl)phosphatidylethanol- 
amine (MPB-PE) was synthesized, purified and analyzed 
as described before [22,23]. MPB-PE was incorporated 
into the liposomal bilayer to couple Fab' fragments cova­
lently to liposomes. Lipid mixtures composed of 
PC/PG/Chol/M PB-PE of varying molar ratios were dis­
solved in chloroform and dried to a thin film by using a 
rotary evaporator at 40° C under reduced pressure. Ra­
dioactive (immuno)liposomes were prepared by addition of 
[3H]cholesteryloIeoylether to the chloroform mixture. Af­
ter evacuation for at least 1 h the lipid film was hydrated 
in Hepes buffer (20 mM Hepes, 135 mM NaCl, pH 7.4) or 
alternatively in CF solution (100 mM CF, 10 mM Tris-HCl, 
pH 7.4). The resulting multilamellar liposome dispersion 
was sequentially extruded through 0.6 /xm and 0.2 /xm 
polycarbonate membranes (Uni-pore, Bio-Rad) under ni­
trogen pressure [24]. Vesicles formed by this procedure 
had on the average 1.5 bilayers as reported by Jousma et 
al. [25]. After extrusion, the outside buffer was exchanged 
by applying ultracentrifugation (80 000 X g, 45 min). The 
pellet was redispersed in acetate buffer (100 mM NaAc, 88 
mM NaCl, pH 6.5) followed by flushing with N2 (g). 
Routinely (unless otherwise stated), freshly prepared lipo­
somes (8 -12  /xmol TL/m l) were incubated with freshly 
prepared Fab' fragments (0.3-0.4 m g/m l) in nitrogen 
atmosphere. Samples were taken to determine the Fab' and 
the lipid concentration during incubation. The coupling 
reaction was carried out at 4° C under constant rotation 
overnight. Finally, the immunoliposomes were separated 
from unconjugated Fab' fragments by ultracentrifugation at 
80 000 X g  during 45 min. The pellet was resuspended and 
washed twice with Hepes buffer. MPB-PE liposomes, not 
incubated with Fab' fragments and further referred to as 
unconjugated liposomes, were exposed to the same treat­
ment. Liposome dispersions were stored at 4°C under 
nitrogen atmosphere.
2.5. Liposome characterization
Lipid phosphate was determined by the colorimetric 
method of Fiske and SubbaRow [26]. Protein was deter­
mined by the method of Wessel [27], with bovine serum 
albumin (BSA) as standard. The amount of monoclonal 
antibody coupled to the liposomes was expressed as ¡xg of 
protein per /xmol of total lipid (TL). At the concentration 
used (100 mM), CF fluorescence is fully quenched. Leaked 
CF will attain in the medium a concentration which allows 
the dye to fluoresce. Before and after destruction of the 
liposomes by addition of 0.5% Triton X-100 and subse­
quent heating (70° C, 30 min), CF fluorescence was as­
sayed at 518 nm emission wavelength and 489 nm excita­
tion wavelength in a Kontron Instruments spectrofluori- 
meter, Model SFM 25 (Watford/Herts, UK) [28]. Ra­
dioactivity was measured in Hionic Fluor as scintillation 
mixture in a Tri-Carb 1500 liquid scintillation counter 
(Packard Instruments, Downers Grove, IL, USA). Mean 
particle size was determined by dynamic light scattering 
(DLS) with a Malvern 4700 system using a 25 mW He-Ne 
laser and the automeasure vsn 3.2 soft-ware (Malvern, 
UK). For viscosity and refractive index the values of pure 
water were used. As a measure of the particle size distribu­
tion of the dispersion the system reports a polydispersity 
index. This index ranges from 0.0 for an entirely mono- 
disperse up to 1.0 for a completely poly disperse disper­
sion. Zeta-potentials were measured in a PC-3 cell with a 
Malvern zeta-sizer IIC (Malvern).
2.6. Release kinetics in buffer and serum
The release characteristics of CF-containing MPB-PE 
liposomes and OV-TL3 immunoliposomes were deter­
mined after incubation for 5, 24 and 48 h in Hepes buffer 
(20 mM Hepes, 135 mM NaCl, pH 7.4) and fetal calf 
serum (FCS) (Gibco). (Immuno)liposomes at a concentra­
tion of approx. 10 /xmol TL/m l were mixed (1:1) with 
buffer or serum. The incubations were performed in dupli­
cate at 37° C under continuous agitation. CF release was 
assayed as described above.
2.7. Tumor model
The human ovarian cancer cell line OVCAR-4 origi­
nated from Dr. Hamilton (National Cancer Institute, 
Bethesda, MD, USA) [29,30] and was maintained in Dul­
becco’s modified Eagle’s medium (DMEM) (Flow Labora­
tories, Irving, Scotland, UK) supplemented with fetal calf 
serum (10%) and glutamine (2 mM), penicillin (100 
units/ml), streptomycin (100 /xg/m l) and Fungizone (0.26 
/xg/m l). An in vivo OVCAR-4 tumor model was devel­
oped in the NMRI athymic nude mice [31] (bred at Harlan 
CPB, Zeist, The Netherlands) by i.p. inoculation of OV­
CAR-4 cells. After establishing the tumor model only i.p. 
ascitic tumor cells were used for serial transfer. The ani-
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mais developed gross ascites 4 -5  weeks after i.p. inocula­
tion with solid tumor growth localized on the diaphragm, 
mesentery and the abdominal wall.
2.8. Cell binding assay
Cell binding assays were performed on in vitro growing 
OVCAR-4 cells or on cells present in ascites collected 
from OVCAR-4 tumor bearing athymic nude mice. Cul­
tured monolayers of OVCAR-4 cells were treated with 
trypsin/EDTA (0.25%/0.02%). A suspension of cells in 
PBS was mixed with an equal volume of CF containing 
(immuno)liposomes. Incubations were performed in dupli­
cate or triplicate under continuous agitation. Unbound 
(immuno)liposomes were separated from the cells by cen­
trifugation (800 X  g, 5 min). The cell pellet was washed 
twice with PBS and resuspended in 0.5 ml PBS containing 
0.5% Triton X-100 (v /v ), followed by heating for 30 min 
at 70° C to lyse cell-bound (immuno)liposomes. After cen­
trifugation at 1500 X  g  during 10 min, supernatants were 
analyzed for CF as described above. In case of radioactive 
(immuno)liposomes the washed cell pellet was transferred 
into a vial and digested by the addition of 1 ml Soluene-350 
at 40° C for one night, yielding a clear solution. Radioac­
tivity was measured in Hionic Fluor as described above.
2.9. Electron microscopy
OV-TL3 immunoliposomes (coupling ratio: 6 fxg 
Fab'/yu-mol TL) and MPB-PE liposomes were adminis­
tered i.p. in OVCAR-4 tumor-bearing NMRI athymic nude 
mice. Solid i.p. tumors (0.5-0.6 g) and ascites (1 -2  ml) 
were present at the time of injection. Each mouse received 
a liposome dose of 8 /xmol TL in 0.5 ml of Hepes buffer 
pH 7.4. After 5 h, the mice were killed and the ascites was 
collected and washed twice with PBS by centrifugation 
(800 X  g, 5 min). The final cell pellet was double-fixed in 
glutaraldehyde-tricomplex fixative (glutaraldehyde- 
potassium ferrocyanide-calcium chloride-cacodylate 
buffer), followed by a postfixation in an osmium-tricom- 
plex solution (osmic acid-potassium ferrocyanide-calcium 
chloride-cacodylate buffer) [32]. Dehydration was per­
formed in an ascending series of ethanols and the cells 
were embedded in Epon 812. Diamond-cut ultrathin sec­
tions with a Reichert OM U3 ultramicrotome were exam­
ined either unstained or uranyl acetate contrasted in a 
Philips EM 300/301 electron microscope.
3. Results and discussion
Factors which should be taken into account when con­
sidering the preparation of immunoliposomes are: (1) a 
sufficient quantity of antibodies must be bound to the 
liposomal surface in a reproducible way; (2) the integrity 
of the liposomes should be preserved during the coupling
process; (3) the liposome-antibody complex must be suffi­
ciently stable on storage and after administration in vivo; 
(4) the homing capacity of the antibodies should be pre­
served after binding to the liposomes.
3.1. Preparation and characterization of antibody (frag­
ment) preparations
The mouse monoclonal antibody OV-TL3 is a promis­
ing candidate for immunotargeting of ovarian cancer. It is 
directed against cell surface antigenic determinants present 
on more than 90% of human ovarian carcinomas of differ­
ent histological types and shows very little affinity for 
nonovarian carcinoma cells [33]. The monoclonal antibody 
RIV1000, in the present studies used as an irrelevant 
monoclonal antibody, is directed against human lympho­
cytes [34].
The purity of the purified antibody preparations (IgG 
and F(ab')2) was confirmed by SDS-PAGE. The p i  values 
of the intact antibodies as well as the F(ab')2 fragments, 
produced by pepsin digestion of the IgG molecules, were 
determined by IEF. For the OV-TL3 antibody the p I 
values of the bands ranged from 6.8 to 7.1 for intact IgG 
and from 8.2 to 8.7 for F(ab')2 fragments. The p i  values 
of the RIV1000 antibody ranged from 5.8 to 6.6 for intact 
IgG and 5.5 to 8.0 for F(ab')2 fragments. This indicates
that the F(ab')2  and therefore also the Fab' fragments of 
the OV-TL3 antibody were positively charged at neutral
pH.
The immunoreactivity of purified IgG and F(ab')2 frag­
ments of OV-TL3 and RIV1000 to OVCAR-4 cells was 
determined using flow cytometry (Fig. 1) The data indicate 
that at the protein concentrations tested the reactivity of 
F(ab')o-0V-TL3 was maintained. In addition, the results
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Fig. 1. Flow cytometric analysis of OV-TL3 and R1V1000 binding to 
OVCAR-4 cells. Percentage positive OVCAR-4 cells as a function of the 
concentration of ( • )  OV-TL3 IgG, (O ) OV-TL3 F(ab')2, U )  RIV1000 
IgG and ( a ) RIV1000 F(ab')2. Cells were examined for cell-associated 
fluorescence by flow cytometry as described in Materials and methods. 
The mean percentage of fluorescent cells determined by flow cytometry 
is presented after subtraction of the percentage of fluorescent cells stained 
after incubation with only fluorescein-conjugate. The S.D. varies between 
1-10% of the mean value. Each point represents at least three experi­
ments.
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illustrate the suitability of the RIV1000 antibody to be 
used as an irrelevant antibody in our studies concerning 
targeting of immunoliposomes to ovarian carcinoma. OV- 
TL3 did not react with nonrelevant target cells (the murine 
squamous cell carcinoma 5D04 [35] and human bladder 
carcinoma T24) in flow cytometric studies (results not 
shown).
For immunospecific targeting Fab' fragments of OV- 
TL3 were covalently linked to MPB-PE liposomes (see 
below). The Fab' fragments were generated from F(ab')2  
fragments by dithiothreitol (DTT) incubation. The experi­
mental conditions used (incubation for 90 min at pH 5.5 at 
room temperature) were taken from Martin and Kung [36]. 
Addition of excess /V-ethylmaleimide to the reaction mix­
ture was used to stop the reduction process. The DTT 
concentration was assessed for a complete reduction of 
F(ab')2 dimers to Fab' monomers. The HPLC profiles 
presented in Fig. 2 show that this is achieved at a DDT 
concentration of 20 mM. The same result was obtained for 
RIV1000 F(ab')2 (results not shown). Therefore, it was 
decided to use routinely 20 mM DDT for the preparation 
of Fab' fragments.
3.2. Choice of preparation method
We prepared routinely multilamellar liposomes (MLV) 
consisting of PC, PG, Choi, and the sulfhydryl-reactive 
phospholipid derivative MPB-PE (2.5 mol%). Bangham 
and co-workers reported on the preparation of MLV for 
the first time [37], and their method has proven to be very 
popular. MLV are suitable for the encapsulation of a 
variety of substances and can be made with a wide variety 
of lipid compositions [38], A difficulty with Bangham’s 
method is the lack of control over the vesicle size distribu­
tion. Therefore, the liposomes were extruded through poly­
carbonate membranes with pore sizes of 0.6 and 0.2 /xm to 
overcome this problem. Interestingly, instead of having a 
multilamellar nature, such extruded liposomes have been 
reported to be uni- or oligolamellar (one to three bilayers) 
[25].
Many different techniques for the coupling of antibod­
ies to liposomes have been described [1,40]. We have used 
one of the most popular conjugation methods involving the 
use of the bifunctional agent MPB-PE [22] (Fig. 3). This 
technique was selected from a number of options for the 
following reasons: (1) mild conditions are maintained dur­
ing coupling, avoiding a decrease in the immunoactivity of 
the coupled antibody fragment; (2) Fab' fragments are 
covalently linked to the MPB-PE anchor present in the 
outer lipid bilayers of preformed liposomes. This method 
presumably results in an adequate orientation of the Fab' 
fragments on the liposomes: the antigen binding sites are 
outward directed and fully accessible to antigen binding. 
Moreover, the thio-ether bridge has proven to be stable in 
vivo, contrary to the alternatively used disulfide bridge; (3) 
the Fc part of the IgG molecule is removed. This can be of
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Fig. 2. Effect of DTT concentration on the reduction of OV-TL3 F(ab')2 
dimers to Fab' monomers. HPLC-analysis on a TSK 3000 SW column 
after reduction of OV-TL3 F(ab')2 at various DTT concentrations: (A) 2 
mM, (B) 10 mM, and (C) 20 mM. Incubations were performed in acetate 
buffer (100 mM NaAc, 88 mM NaCl, pH 5.5) for 90 min. The reduction 
process was stopped after addition of excess NEM (see Materials and 
methods). The molecular weights were estimated by plotting the molecu­
lar weights of the injected standards against their retention times. The 
first peak corresponded to a molecular mass of 90 kDa (OV-TL3 F(ab')2) 
and the second with 43 kDa (OV-TL3 Fab').
great importance for in vivo use of Fab' vesicles. In this 
way the Fc receptor of macrophages is not activated and 
elimination of the liposome, by the mononuclear phago-
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cyte system (MPS), might be reduced and slowed down
[14].
3.3. Optimization of the coupling of Fab' to MLV
Coupling of a (sulfhydryl-group exposing) protein to 
liposomes containing maleimide residues merely requires 
mixing of the liposomes and the protein, which has been 
reduced and separated from DTT. The coupling efficiency 
was investigated under various reaction conditions. The 
liposomes used were composed of PC, PG, Choi and 2.5 
mol% MPB-PE (38.5:4:16:1.5 molar ratio).
The stability of the maleimide group of MPB-PE is 
known to be sensitive to pH [41]. Especially at pH values 
greater than 7.0 rapid degradation of the maleimide residue 
has been reported [42]. A pH of 6.5 was recommended for 
use in the coupling reaction [22,43]. This pH was also used 
in our studies. However, as the marker carboxy fluorescein 
(CF), occasionally entrapped to monitor cell binding, be­
comes protonized and loses its charge at low pH [28,44], 
the preformed MPB-PE liposomes were prepared and stored 
at a pH of 7.4. The MPB-PE vesicles were used as freshly 
as possible; the maleimide function was exposed to pH 7.4 
for maximally 8 h. Nevertheless, it was investigated 
whether the relatively short exposure to pH 7.4 may cause 
a significant loss of maleimide reactivity which might then 
be expected to result in a drop in coupling efficiency. 
Liposomes containing 2.5 mol% MPB-PE were prepared at 
pH 5 .5 as well as at pH 7.4 under standard experimental 
conditions (described in Materials and methods). Fab' 
fragments were coupled to the freshly prepared vesicles at 
pH 6.5. The protein to lipid ratios (coupling ratios) were 
similar and amounted to 9.5 /xg Fab'//xmol TL and 10.7 
fig Fab'//Amol TL for the ‘pH 5.5 dispersion’ and the ‘pH 
7.4 dispersion’, respectively. These results indicate that we 
could use a pH of 7.4 during our standard preparation 
procedure prior to Fab' coupling. Results of Peeters et al.
Table 1
Coupling efficiency and incubation time
Incubation Incubation Coupling Coupling
time temperature ratio efficiency a
(h) C C ) ( jxg Fab' /  /¿mol TL) (%)
0.5 20 2.8 8
1.5 20 6.0 17
14 4 11 31
Freshly prepared OV-TL3 Fab'-fragments (0.37 m g/m l) were incubated 
with MPB-PE liposomes (PC /PG /C hol/M PB-PE; 38.5:4:16:1.5) (10.4 
/¿mol T L /m l) under N2 atmosphere. At the time indicated the réaction 
was stopped by addition of excess NEM. The coupling ratio at each time 
point was determined following separation of Fab'-liposomcs from unre­
acted Fab'-fragments by ultracentrifugation as described in Materials and 
methods. A typical experiment out of two performed is shown. 
u Coupling efficiency (%) was calculated by dividing the final coupling 
ratio by the ratio of protein to lipid present during the coupling reaction X
[45] and Loughrey et al. [42] indicate that the exposure to 
pH 7.4 for prolonged periods (>  8 h) results in a decrease 
of coupling efficiency. Therefore, in line with their results, 
the time span between the start and the end of exposure to 
this pH never exceeded 8 h.
It has been reported that an incubation time of 6 h is 
sufficient for protein conjugation to MPB-PE liposomes 
[43]. For reasons of practical convenience it was examined 
whether the coupling reaction could proceed overnight 
Table 1 presents results of the effect of incubation 
time/temperature on the coupling ratio of the reaction 
product. It was found that under typical reaction conditions 
as described in Materials and methods much more of the
added OV-TL3 Fab' was coupled to liposomes
overnight (14 h) than in the shorter incubation time peri­
ods. Bredehorst et al. [46] studied the time course of the 
coupling reaction over a period of 20 h. They observed 
that the coupling ratio reached a plateau value in about 5 h 
after start of incubation. Based on their and our results, it
Antigen combining sites
- l" l “ Pepsin » -a DTT m m
F(ab') 2 Fab'
2
IgG
o
pH 6.5
NH-C—(CH.)
MPB-PE liposome Fab'-immunoliposome
Fig. 3. Schematic representation o f the coupling o f Fab' fragments to MPB-PE liposomes. F(ab')2 fragments are prepared by pepsin digestion of IgG. Fab' 
fragments are generated by reduction of F(ab')2 with DTT at pH 5.5. After removal of DTT, Fab' fragments are immediately mixed with MPB-PE 
liposomes at pH 6.5 and allowed to react under N 2 atmosphere overnight. The sulfhydryl group of the Fab' fragment forms a stable thioetlier cross-linkage 
with the double bond of the maleimide moiety on the surface of the MPB-PE liposomes (from Ref. [22]).
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Table 2
Effect of mol fraction of liposomal MPB-PE on the coupling efficiency
MPB-PE
(mol %)
Incubation 
ratio a
( /xg Fat///¿m ol TL)
Coupling
ratio
( ¡xg Fab'/jtxmol TL)
Coupling 
efficiency b 
(%)
0 ........... ...........4 7 ’" 0.04 0.09
1 40 9.1 23
2.5 36 11 31
5 37 17 46
Freshly reduced OV-TL3 Fab'-fragments (0.37 m g/m l) were mixed with different MPB-PE-liposome dispersions varying in mol% MPB-PE 
(PC/PG/Chol/M PB-PE; 40 — jc:4: 16: jc) (7.8-10,4 ¿¿mol T L /m l) and allowed to react under N2 atmosphere at 4°C  for 14 h. The coupling ratio was 
determined following separation of Fab'-liposomes from unreacted Fab'-fragments by ultracentrifugation as described in Materials and methods. A typical 
experiment out of two performed is shown.
a Ratio of protein and lipid present during the coupling reaction.
Coupling efficiency (%) was calculated by dividing the coupling ratio by the ratio of protein to lipid present during the coupling reaction X 100%.
was decided to use overnight incubation for Fab' coupling 
at 4° C.
An important factor influencing the ultimate coupling 
ratio (expressed as fig Fab'//¿mol TL) is the mol fraction 
of MPB-PE in the liposomes. Table 2 shows the increase 
in the amount of coupled Fab' with an increasing mol 
fraction of MPB-PE. No nonspecific binding of Fab' to the 
liposomes was observed (Table 2). Coupling efficiencies 
of up to 30 to 50% were readily achieved under the 
standard experimental conditions employed (as described 
in Materials and methods). The efficient coupling of pro­
tein to liposomes containing lower levels of MPB-PE is of 
particular importance as higher concentrations of this an­
chor molecule (>  2.5 moI%) dramatically affected lipo­
some stability [46]. For this reason we have chosen, as 
other investigators [22,47], 2.5 mol% MPB-PE (on a total 
lipid basis) as the standard maleimide content of the 
liposomes.
The amount of coupled Fab' molecules to 2.5 mol% 
MPB-PE liposomes could be varied by changing the initial 
Fab' concentration or by changing the liposome concentra­
tion in the coupling reaction mixture (Fig. 4). The relation­
ship between coupling ratio and Fab' concentration ap­
peared to be linear over the concentration range from 0.1 
to 0.7 m g/m l of Fab' fragments. In addition, the coupling 
ratio appears to be inversely correlated with the total 
liposome concentration in the reaction mixture. Interest­
ingly, by increasing the Fab' concentration or decreasing 
the lipid concentration in the incubation mixture the cou­
pling efficiency increased and leveled off at 30%. Flexibil­
ity of the method for adjusting desired coupling ratios is 
illustrated. Routinely, we used approx. 0.3-0.4 fig Fab'/ml 
and approx. 8-12 fimol TL/m l for the preparation of 
OV-TL3 (and RIV1000) immunoliposomes.
3.4. Characterization
A proper physicochemical characterization of immuno­
liposomes is not always included in the literature reports. 
The physicochemical properties of immunoliposomes will 
strongly influence their disposition in vivo and their behav­
ior in vitro [48,49]. Therefore, it is important to prepare 
immunoliposomes well characterized in terms of Fab' cou­
pling ratio, particle size and surface charge, with accept-
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Fig. 4. Coupling of Fab' to liposomes: Fab' concentration (left) and lipid concentration (right) dependence. PC /PG /C hol/M PB-PE  (38.5:4:16:1.5, molar 
ratio) liposomes (left panel: 10.2 /U.mol T L /m l; right panel: various concentrations) were incubated under N2 atmosphere at 4° C in acetate buffer (100 
mM NaAc, 88 mM NaCl, pH 6.5) overnight with freshly prepared OV-TL3 Fab' fragments (left panel: various concentrations; right panel 0.18 mg 
Fab'/ml). The coupling ratio (/xg  Fab'/yxmol TL) was determined following separation of Fab' liposomes from unreacted Fab' fragments by 
ultracentrifugation as described in Materials and methods. Coupling efficiency (%) was calculated by dividing the coupling ratio by the ratio of protein to 
lipid present during the coupling reaction X 100%. Results of a typical experiment out of three performed are shown.
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able long term stability and preservation of immuno- 
reactivity.
Characteristics of standard preparations of the OV-TL3 
and the RIV1000 immunoliposomes are presented in Table 
3. The protein to lipid (coupling ratio) varied only slightly 
between the different immunoliposome preparations. It 
was estimated that at a coupling ratio of 10 ¡jlg Fab'//m ol 
TL approx. 240 Fab' molecules were present on one 
liposome particle. By covalent attachment of OV-TL3 Fab' 
fragments to the MPB-PE liposomes the negative zeta- 
potential was altered from —24 ± 2  mV to —17 + 1 mV 
for the MPB-PE lioosomes and the OV-TL3 immunnlinr»-
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sonies, respectively. The mean diameter was found to be Fig- 5. Particle size stability of (immuno)liposomes as a function of Fab'
approx. 0.25 fim  with low polydispersity indices for both density- The mean particle diameter of liposomes with and without Fab'
------- —  .. . . ... OV-TL3 coupled was measured as described in Materials and methods at
various days after storage at 4° C under N2 atmosphere. Results derived 
from four preparations out of eleven preparations are shown. The S.D. 
varies between 0.2 and 2% of the mean value. Coupling ratios amounted
MPB-PE liposomes and immunoliposomes on the day of 
preparation. Bredehorst et al. [46] observed that coupling 
of Fab' fragments to liposomes containing 5 mol% MPB-
PE caused a Fab' concentration-dependent increase in size to: 21 /¿g Fab'//xmoi TL, ( ■ )  11 fig Fab'/^m oi t l ,  (O ) 4 fig 
and polydispersity of the liposomes directly upon prépara- F ab '//m o l TL, and ( • )  0 /xg FabV/wnol TL (unconjugated MPB-PE
tion. Under the experimental conditions used in this study 
(see legend Table 3) these effects were of minor impor­
tance.
liposomes).
3.5. Stability
The following aspects concerning the stability of the 
OV-TL3 immunoliposomes were examined: (1) the occur­
rence of changes in vesicle size; (2) retention of entrapped 
contents; (3) influence of serum on the retention of en­
trapped contents; (4) preservation of immunoreactivity on 
storage. The liposomes contained entrapped CF as a fluo­
rescent marker for monitoring liposomal stability.
The mean particle size of immunoliposomes with differ­
ent coupling ratios (up to 21 fig Fab'//xmol TL) changed 
slightly during storage of the dispersion at 4° C for a 
period of 4 weeks (Fig. 5). No change in polydispersity 
index was found for the MPB-PE liposomes (pd 0.15) 
during 4 weeks of storage and a moderate increase in 
polydispersity from 0.14 to 0.22 was measured for OV-TL3 
immunoliposomes with a coupling ratio of 21 /xg 
Fab'//xmol TL (results not shown). A slight increase in 
mean particle size was observed with increasing number of 
Fab' fragments coupled per liposome (Fig. 5). The loss of
Table 3
Characterization of standard preparations of MPB-PE liposomes, OV-TL3 immunoliposomes and RIV1000 immunoliposomes
Characteristics MPB-PE
liposomes
OY-TL3
immunoliposomes
RIV1000
immunoliposomes
Coupling ratio ( fig Fab'//xmol TL) 1 - 10.2 ±  1.5 (n =  8) 9.1 ±  0.9 (n =  5)
Coupling efficiency (%) ll ---------- 32 ± 8 ( » - 7 ) 30 ± 6 ( n  =  4)
Estimated number of Fab' per liposome c < * im i 240 240
Zeta-potential (mV) - 2 4  ± 2  (« =  5) — 1 7±  1 ( n - 4 ) ----------
Mean particle diameter ( jam) 0.26 ±  0.03 ( n -  5) 0.25 ±  0.02 (n = 8) 0.26 ±  0.02 (n -  5)
Polydispersity index d 0.16 ±  0.04 ( n -  5) 0.15 ±  0.03 (« = 8) 0.15 ± 0 .4  ( /I - 5 )
MPB-PE liposomes, OV-TL3 and RIV1000 immunoliposomes were prepared according to the standard method described in Materials and methods. 
Freshly reduced OV-TL3 and RIV1000 Fab'-fragments (concentrations varying between 0.29 and 0.37 mg/ml) were mixed with MPB-PE-liposomes 
(PC /PG /C hoi/M PB-PE; 38.5:4:16:1.5) (concentrations varying between 8.0-11.6 /imol TL/ml) and allowed to react under N2 atmosphere at 4° C
overnight.
1 The coupling ratio ( /j,g Fab'//xmol TL) was determined following separation of Fab'-liposomes from unreacted Fab'-fragments by ultracentrifugation as 
described in Materials and methods.
h Coupling efficiency (%) was calculated by dividing the coupling ratio by the ratio of protein to lipid present during the coupling reaction X 100%. 
c The number of Fab' molecules coupled per liposome, at a coupling ratio of 10 yu,g Fab'/>mol TL, was estimated using the following assumptions: a 
molecular weight of Fab' of 50 kDa; surface area of 29 • 1010 /xm2//im o l TL; an average number of 1.5 bilayers as determined for almost identically 
prepared P C /P S /C h ol (10:1:4) liposomes (25); mean particle diameter of 0.25 /xm. A total liposomal surface area of 0.59 fim2 per liposome and a
number of 5 • 10n liposomes per /xmol TL were calculated.
 ^ Polydispersity index is a measure o f the particle size distribution of the dispersion. This index ranges from 0 for an entirely monodisperse up to 1 for a
completely polydisperse dispersion.
Dashes indicate not determined.
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Fig. 6. Effect of the coupled amount Fab' on the zeta-potential of 
OV-TL3 immunoliposomes. Zeta-potentials of OV-TL3 ¡mmunolipo- 
somes with varying coupling ratios are presented. The data shown refer to 
the preparations used for the experiment presented in Fig. 5.
negatively charged molecules in the bilayers contributes to 
prevention of aggregation (and/ or fusion). The zeta-poten­
tial of the immunoliposomes and the Fab' coupling ratio 
appear to be linearly related: the higher the coupling ratio, 
the lower the negative zeta-potential (Fig. 6). The decrease 
in negative zeta-potential as a function of coupling ratio is 
most likely related to our observation that the OV-TL3 
Fab' fragments are positively charged at neutral pH (see 
above). The neutralizing capacity of increasing amounts of 
coupled Fab' leading to reduced electrostatic repulsive 
forces may induce a tendency of immunoliposomes to 
aggregate. Interestingly, literature reports on increases in 
size and polydispersity are based on studies employing 
immunoliposomes with coupling ratios by far exceeding 
those used in the present study [36,46].
CF over a 3-week period storage was minimal ( <5%;  
results not shown). The permeability of liposomes was also 
studied in the presence of fetal calf serum. The MPB-PE 
liposomes and the OV-TL3 immunoliposomes showed only 
minor CF leakage during incubation in 50% serum at 
37° C for 2 days (results not shown). With respect to 
preservation of immunoreactivity, the capacity of the im­
munoliposomes to bind to in vitro cultured ovarian carci­
noma cells was maintained after storage for 1 month at 
4° C (results not shown).
Various coupling procedures have been reported with 
detailed analysis of coupling efficiency, preservation of 
antibody activity, and stability of the cross-link between 
antibody and liposome [3]. However, very few studies 
have addressed the stability of immunoliposomes on stor­
age. Bredehorst et al. [46] observed that covalent coupling 
of Fab' fragments to preformed MPB-PE liposomes can 
have major effects on liposomal integrity, size, and poly­
dispersity. Such effects were not observed in this study. In 
general, inclusion of sufficient amounts of cholesterol is 
important to obtain liposomes with low permeability char­
acteristics [50]. In addition, it is likely that the presence of
3.6. Binding to ovarian carcinoma cells
As specific association of immunoliposomes with their 
target cells is a necessary requirement for target-specific 
drug delivery, we evaluated the binding of OV-TL3 im­
munoliposomes containing CF as an aqueous marker to the 
OVCAR-4 human ovarian tumor cell line. Measurements 
of cell binding after incubation with cells at 37° C may 
include both binding and uptake; therefore, cell binding 
was studied at 4° C since endocytosis does not occur at this 
temperature [51,52]. To show specificity of the OV-TL3 
immunoliposomes towards the OVCAR-4 cells, negative 
control binding experiments were performed. OV-TL3 im­
munoliposomes were incubated with nonovarian carci­
noma cells, the murine gastric squamous cell carcinoma 
5D04 was used [35]. In addition, the degree of cell 
binding towards OVCAR-4 was determined for nonspe­
cific immunoliposomes (bearing the irrelevant antibody 
RIV1000), MPB-PE liposomes, liposomes without incor­
porated MPB-PE and liposomes without incorporated 
MPB-PE preincubated with OV-TL3 Fab' fragments. All 
these negative control incubations resulted in very low
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Fig. 7. Cell binding: lipid concentration dependence. CF-containing ( • )  OV-TL3 immunoliposomes (11 fxg Fab'//tm ol TL) and ( x )  MPB-PE liposomes 
were incubated at varying liposome concentrations with in vitro growing OVCAR-4 cells (106 cells/m l) for 90 min at 4° C. Results are presented as: (A) 
the absolute amount of (immuno)liposomes bound and (B) % of added liposomes bound. Results of a typical experiment out of three performed are shown.
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performed are shown.
binding values. In Figs. 7 -9  only the control data obtained 
with MPB-PE liposomes and RIV1000 immunoliposomes 
are presented.
Fig. 7 shows the degree of (immuno)liposome binding 
to OVCAR-4 cells after 1.5 h of incubation at 4° C. As the 
concentration of added OV-TL3 immunoliposomes was 
increased (at a constant cell concentration), the absolute 
amount of bound immunoliposomes increased (A), while 
the fraction bound decreased (B). The opposite was the 
case when the tumor cell concentration was increased (at a 
constant liposome concentration) (Fig. 8). It was estimated 
that approx. 3.5 • 104 liposomes were bound per cell at a 
binding ratio of 70 nmol T L /1 0 fi cells (Fig. 8). Fig. 9 
shows the dependency of the degree of cell binding on the 
incubation time. Under the chosen conditions, cell binding 
was maximal within 0.5 h after start of the incubation, 
demonstrating that an incubation time of 1.5 h was suffi­
cient.
All in vitro incubations presented so far were performed 
at 4° C. In view of the in vivo situation, it was of interest
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Fig. 9. Cell binding: incubation time dependence. CF-containing ( #  ) 
OV-TL3 immunoliposomes (9,7 f ig F ab'//i.m ol TL) and (X )  MPB-PE 
liposomes were incubated at a lipid concentration of 0.27 /¿mol T L /m l 
with in vitro growing OVCAR-4 cells (106 ce lls /m l) at 4° C. Results are 
presented as the absolute amount of (immuno)liposomes bound. Results 
of a typical experiment out of two performed are shown.
to compare the binding capacity of the OV-TL3 i
posomes at 4° C and at 37 C. As we observed cell- 
ted leakage of liposomal CF during incubation at 37" C 
[8,53,54], we did not use CF as liposomal marker. Instead 
[3H]cholesteryloleoylether was incorporated in the liposo­
mal bilayers as this lipid has proven to be a reliable marker 
for monitoring liposomes in vivo [55,56], Fig. 10 shows 
that the cell binding profiles obtained at both temperatures 
are comparable. This finding suggests that, if internaliza­
tion of bound liposomes occurs, this process is relatively 
slow. Recent experiments are in agreement with this sug­
gestion as they did not provide 
cellular internalization of the relatively large (about 0.25 
/¿m), cell-bound immunoliposomes
requires a high rate of i
the surface receptor (e.g., 
usually internalize its ligand [59]) in combination with a
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small size (i.e., less than about 0.1 ¿tm) of the bound 
liposomes.
Specific binding was additionally demonstrated on in 
vivo propagated OVCAR-4 cells harvested in ascites form. 
As these cells grew in large cell clusters it was not 
possible to determine the cell concentration. Therefore, no 
comparison can be made with the in vitro propagated
binding percentages amounted to 34 ±  1% (mean ±  S.D. 
of three incubations) for the OV-TL3 immunoliposomes (6 
fjug Fab'//xmol TL) and 1.0% (mean of two incubations, 
individual values deviated 0.1% from the mean) for MPB- 
PE liposomes.
Finally, Fig. 11 shows electron micrographs of in vivo 
growing OVCAR-4 cells 5 h after i.p. administration of
OVCAR-4 cells with regard to cell binding capacity. The (immuno)liposomes. These EM micrographs revealed im
performed by mixing (1:1) freshly 
vested ascites with CF-containing (immuno)liposomes (16 
fjbmol TL/ml). Under the experimental conditions cell
munoliposomes associated with exposed tumor cells con­
firming the ability of OV-TL3 immunoliposomes to bind 
to ovarian carcinoma cells in vivo. Negative control exper-
A
f t ,  : i  ; V:L, 
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Fig growing OVCAR-4 cells 5 h after (immuno)liposome administration. OV-TL3 immunoliposomes (6
OVCAR-4 tumor-bearing NMRI athymic nude
after injection ascites was collected and treated as described in Materials and methods. Electron micrographs showing OVCAR-4 ascitic cells after
(D) 0.2 jjitn.
(A) unconjugated MPB-PE liposomes* (B -D ) OV-TL3 immunoliposomes
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Fig, 11 (continued).
iments with MPB-PE liposomes did not reveal any interac­
tion upon inspection.
3.7. Concluding remarks
Immunoliposomes bearing antibodies which are di­
rected against cell surface antigens such as those associ­
ated with transformed cells, may have therapeutic poten­
tial. However, at the present time, such targeted liposomal 
systems have mainly been used for in vitro applications 
such as diagnostic assays [57]. In order to exploit the full 
potential of antibody-targeted carrier systems a versatile 
and reliable methodology for coupling is required. This 
report addresses an established method for the binding of
Fab' fragments of OV-TL3 (monoclonal anti-ovarian carci 
noma IgG) to
anchor MPB-PE. The amount of protein bound to the 
vesicles can be controlled within limits by varying the 
protein and/or lipid concentration in the coupling reaction 
mixture. The product was stable over at least 3 
terms of leakage of encapsulated CF, particle size and 
antigen binding capacity. OV-TL3 immunoliposomes were 
shown to bind specifically to OVCAR-4 target cells in 
vitro and in vivo. The subsequent events which follow cell 
binding are currently under investigation since liposome
in
the encapsulated drug into the target cell. Uptake of im­
munoliposomes by target cells has been shown to occur
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via receptor-mediated endocytosis, which varies consider­
ably from one surface receptor to another and from one 
cell type to another [60]. Recent results from our labora­
tory did not provide evidence that internalization of OV- 
TL3 immunoliposomes by the OVCAR-4 tumor cells is of 
quantitative importance [58]. One future objective is to use 
other homing ligands directed to surface receptors known 
to be internalized by cells at a high rate, and conjugate 
them with target cell specific small-sized immunolipo­
somes. Several other options for drug entry into the target 
cell which do not depend on internalization of the carrier 
are also under investigation. One option is that the encap­
sulated drug simply leaks out of the cell-bound immunoli­
posomes in the close proximity of the tumor cell. A 
sufficiently high concentration gradient over the cell mem­
brane may result in considerable cellular drug uptake. 
Special attention is additionally focused on the use of 
‘special function’ immunoliposomes from which release of 
entrapped agents is triggered by environmental manipula­
tions (e.g., by a slight change of the temperature or pH) 
after their binding to the tumor cells [3,4],
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